Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to test the effectiveness and safety of PROCRIT (Epoetin alfa)
at a higher starting dose (60,000 Units) once per week, followed by a less frequent dose
(60,000 Units every two weeks) in patients with cancer and chemotherapy induced anemia.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.